Barrington Research analyst Vincent Colicchio maintains Perficient (NASDAQ:PRFT) with a Outperform and lowers the price target from $110 to $80.
Dialysis Player Fresenius Medical’s Q4 Sales Hold Steady: Details
Fresenius Medical Care Q4 2023 revenue: €4.9 billion. Patient volume growth is expected at 0.5%-2% in 2024.